70% chance of favorable weather for this evening's ULA launch from Florida
April 28 (UPI) -- United Launch Alliance on Monday plans to launch Amazon's first 27 satellites after earlier launch plans were scrubbed nearly three weeks ago because of inclement weather in Florida.
Liftoff for Kuiper-1 is scheduled for 7 p.m. EDT from pad 41 at Cape Canaveral Space Force Station. There is a two-hour launch window, and it can be pushed back to Tuesday in case of bad weather again or technical problems.
There is a 10-mile ring around the launch site for weather considerations.
On Monday, weather conditions were listed as 70% favorable, according to ULA.
The 106.5-foot Atlas 551 booster will put 27 Kuiper satellites into orbit at an altitude of 280 miles for high-speed Internet access to millions of people around the world.
The Atlas V 551 rocket is configured with five side-mounted solid rocket boosters and a medium-length payload fairing, according to ULA. The rocket elements were assembled inside the Vertical Integration Facility adjacent to the launch pad.
Amazon plans to launch 3,232 Kuiper satellites by 2029, including half by mid-2026.
The Federal Communications Commission in February 2023 approved the entire Project Kuiper after ULA dealt with the risks of orbital debris.
Last week, ULA President and CEO Tony Bruno said the company is targeting late spring or early summer for its next Kuiper Atlas launch. The company also is planning its first national security mission via a Vulcan rocket.
In October 2023, ULA launched two prototype Kuiper satellites into orbit for testing.
Amazon is building the satellites in Kirkland, Wash.
"We've designed some of the most advanced communications satellites ever built, and every launch is an opportunity to add more capacity and coverage to our network," Rajeev Badyal, vice president of Project Kuiper, said in a pre-launch blog posting. "We've done extensive testing on the ground to prepare for this first mission, but there are some things you can only learn in flight, and this will be the first time we've flown our final satellite design and the first time we've deployed so many satellites at once."
Rival SpaceX has launched 7,000 Starlink satellites for more than 5 million subscribers. Also, Eutelsat OneWeb also is entering the market for low Earth orbit satellites for internet usage.
United Launch Alliance LLC was formed in December 2006 as a joint venture between Lockheed Martin Space and Boeing Defense, Space & Security.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
23 minutes ago
- Miami Herald
MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition
Oral therapy designed to minimize CNS side effects shows dual activity in weight loss and smoking cessation models without muscle loss MIAMI, FLORIDA / ACCESS Newswire / June 30, 2025 / MIRA (NASDAQ:MIRA) today announced new animal study results from SKNY-1, a next-generation oral therapeutic under definitive agreement for acquisition. In a zebrafish model that mimics human obesity and craving behaviors, SKNY-1 demonstrated weight loss, suppression of appetite and craving for high-calorie diets, and reversal of nicotine-seeking behavior-all achieved within six days of oral treatment. SKNY-1 is being developed as an oral alternative to GLP-1 injectables, which are often limited by nausea, GI discomfort, injection reaction, and growing concerns around muscle loss. Unlike GLP-1s, which reduce both fat and lean mass, SKNY-1 demonstrated significant weight loss with preserved muscle. It was specifically designed to minimize engagement with central nervous system pathways implicated in the psychiatric side effects observed in some smoking cessation therapies and first-generation CB1-targeting weight-loss drugs. The data support SKNY-1's potential as a differentiated oral therapy addressing two of the world's leading causes of preventable death. The study was conducted in an obesity and craving model in Ob42 Strain-mc4r (G894C) mutated zebrafish following six days of oral treatment with two doses of SKNY-1 and was compared to normal controls. Key Results Weight Loss and Muscle Preservation:SKNY-1 reduced body weight by approximately 30% after just six days of oral treatment. Treated animals ended up weighing about 10% less than healthy controls. Importantly, this weight loss was not accompanied by muscle density changes-suggesting SKNY-1 helps burn fat while preserving lean body mass. Metabolic Activity and Ventilation Rate:Treated animals showed an increase in breathing rate, which is a reliable signal that their metabolism was speeding up. This aligns with the observed weight loss and suggests that SKNY-1 helps the body burn more energy. Liver and Lipid Profile Improvements:In untreated obese animals, fat buildup in the liver was about 50% higher than normal. SKNY-1 reversed this buildup, bringing liver fat back to healthy levels. At the same time, cholesterol levels-including LDL ('bad' cholesterol) and HDL ('good' cholesterol)-also returned to normal, without affecting fat levels in the blood. This points to improved fat processing without disrupting the body's overall metabolic balance. Appetite, Craving, and Compulsive Eating:Obese animals were eating 2-3 times more high-calorie food than normal. SKNY-1 dose-dependently reduced this behavior-high-dose animals ate less than healthy controls. The drug also made the animals less likely to pursue food in stressful environments and reduced obsessive food-seeking in tests designed to measure craving. Nicotine Craving and Compulsivity:SKNY-1 significantly reduced the desire to seek out and consume nicotine. Treated animals were less willing to pursue nicotine even in stressful conditions, and they no longer showed a preference for environments linked to nicotine rewards. At the high dose, their behavior matched that of healthy animals with no nicotine craving. Neurohormonal Balance:Obese animals had extremely high levels of leptin (a hunger-regulating hormone) and unusually low levels of ghrelin (the 'hunger signal'). This imbalance often leads to constant hunger and poor appetite control. SKNY-1 normalized both hormones, improving the body's ability to regulate hunger and energy use. Brain Dopamine Regulation:Obese animals had too much dopamine in the brain, likely tied to increased reward and cravings. SKNY-1 reduced these dopamine levels-but only at the lower dose. The high dose did not affect dopamine, suggesting the drug can reduce craving without overstimulating the brain. "Within just six days, we saw robust behavioral, hormonal and metabolic changes, including weight loss, improved fat metabolism, and reversal of craving-like behaviors," said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. "These results highlight SKNY-1's potential to address both obesity and nicotine addiction through unique and safe pathways." A Differentiated Approach to Two Major Markets Current weight-loss therapies like semaglutide and tirzepatide are effective but limited by gastrointestinal side effects, injectable administration, and loss of lean mass. Smoking cessation treatments such as varenicline and bupropion carry psychiatric warnings and offer modest long-term quit rates. SKNY-1 was designed to overcome these limitations. It selectively modulates CB1 receptors by blocking β-arrestin signaling-associated with cravings and compulsive behavior-while preserving G-protein signaling, which supports emotional and cognitive stability. The compound also activates CB2 receptors and mildly inhibits MAO-B without affecting MAO-A, supporting a favorable safety and tolerability profile. "These results position SKNY-1 as a potentially disruptive oral treatment," said Erez Aminov, CEO of MIRA. "Its ability to reduce body mass, suppress cravings, and preserve muscle-all through oral administration-makes it a compelling therapeutic candidate as we move toward closing the acquisition and preparing for IND-enabling studies." The Company believes these findings further support the advancement of SKNY-1 toward Investigational New Drug (IND)-enabling studies. With obesity and smoking representing two of the leading causes of preventable death-and a combined global market opportunity exceeding $200 billion-MIRA intends to prioritize SKNY-1 as a potential cornerstone asset pending completion of the acquisition of SKNY Pharmaceuticals, Inc. About MIRA Pharmaceuticals, Inc. MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as anxiety, cognitive decline, neuropathic pain, obesity, and addiction. Cautionary Note Regarding Forward-Looking Statements This press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact:Helga Moyainfo@ 432-9792 SOURCE: MIRA Pharmaceuticals
Yahoo
33 minutes ago
- Yahoo
5 Revealing Analyst Questions From 1-800-FLOWERS's Q1 Earnings Call
1-800-FLOWERS faced a difficult first quarter, as the market responded sharply to results that missed Wall Street's expectations. Management attributed the shortfall to both external and internal factors, including declining consumer sentiment, increased tariffs, and expensive digital marketing channels that failed to yield expected returns. CEO Jim McCann was notably self-critical, describing the company's order management system rollout as a 'colossal screw-up' that impacted sales and customer satisfaction, particularly in the Harry & David brand. The leadership team also acknowledged the loss of lower-income customers and a promotional market environment as key contributors to the quarter's underperformance. Is now the time to buy FLWS? Find out in our full research report (it's free). Revenue: $331.5 million vs analyst estimates of $364.2 million (12.6% year-on-year decline, 9% miss) Adjusted EPS: -$0.71 vs analyst estimates of -$0.34 (significant miss) Adjusted EBITDA: -$34.92 million vs analyst estimates of -$12.43 million (-10.5% margin, significant miss) Operating Margin: -16.7%, down from -6.4% in the same quarter last year Market Capitalization: $326.1 million While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Anthony Lebiedzinski (Sidoti and Company) asked about the impact of holiday timing and the Easter shift on sales. CEO Jim McCann and CFO James Langrock confirmed that holiday placement helped, but everyday business remained soft, and the Easter shift materially affected year-over-year comparisons. Lebiedzinski (Sidoti and Company) questioned the financial and operational impact of the order management system issues. McCann called the implementation a 'colossal screw-up' and Langrock estimated at least $20 million in lost sales and $11 million in incremental costs over two quarters. Lebiedzinski (Sidoti and Company) sought details on the Celebrations Wave timeline, asking what could be achieved in the first year. Management outlined near-term steps including new app capabilities, expanded relationship management tools, and AI-powered personalization for customer engagement. Michael Kupinski (NOBLE Capital Markets) asked whether revenue weakness was concentrated among higher or lower-income customers. President Tom Hartnett stated the biggest declines were among lower-income consumers, while higher-end customers continued to spend on premium items. Doug Lane (Water Tower Research) inquired about the decision to exit retail during COVID and prospects for returning to physical stores. McCann admitted the closure was a mistake and discussed plans for further holiday pop-ups and select permanent store locations based on recent positive results. In the coming quarters, the StockStory team will watch for (1) measurable reductions in customer acquisition costs from the Celebrations Wave ecosystem, (2) progress on resolving order management and system implementation issues, and (3) stabilization or recovery in everyday gifting demand outside of major holidays. Additional attention will be paid to early traction from the company's AI-driven personalization features and any material impacts from changes in tariff policy or consumer sentiment. 1-800-FLOWERS currently trades at $5.13, down from $5.80 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
UPI
an hour ago
- UPI
U.K.-U.S trade deal cutting tariffs on cars, beef, ethanol goes live
A British-American trade deal meaning the vast majority of British car exports to the United States will be subject to a preferential 10% tariff rate, compared with 27.5% for all other countries, came into effect Monday. File Photo by Phil McCarten/UPI | License Photo June 30 (UPI) -- A tariff-busting trade deal between Britain and the United States came into force Monday, slashing U.S. tariffs on imports of British cars, including Jaguar, Range Rover, Aston Martin and Mini by 17.5% to 10% and eliminating a 10% tariff on aerospace sales such as jet engines and aircraft parts. The Department of Business and Trade said in a news release that the "landmark" deal would protect significant numbers of British jobs and save two key industries hundreds of millions of dollars a year lost from higher prices to U.S. customers and stressed that Britain was the only country to have secured this deal with the United States. It said the auto industry employed hundreds of thousands of people, while removing the 10% tariff on imports of aero engines and aircraft parts would make companies in the sector, including Rolls Royce, a major global manufacturer of jet engines, more competitive and enable them to keep driving technological advances. The deal on cars is subject to a 100,000-unit annual quota, roughly equivalent to all vehicles sold to the United States in 2024, which were worth $12.4 billion with an average price of $121,000, according to Office for National Statistics figures. In return, Britain will axe tariffs of 20% and 19% on imports of U.S. beef and ethanol and hike the tariff-free quota to 13,000 tons and 370 million gallons a year, respectively. Hailing the so-called Economic Prosperity agreement, which was finalized with U.S. President Donald Trump two weeks ago on the sidelines of the G7 summit in Canada, Prime Minister Keir Starmer said the deal would benefit critical British industries. "Our historic trade deal with the United States delivers for British businesses and protects U.K. jobs. From today, our world-class automotive and aerospace industries will see tariffs slashed, safeguarding key industries that are vital to our economy," he said. "We will always act in the national interest -- backing British businesses and workers, delivering on our Plan for Change." Britain was the first country to negotiate a deal after Trump announced what he said were reciprocal tariffs on the United States' trading partners on April 2, as high as 49%. Britain escaped with a baseline 10% goods tariff, the lowest of any major trade partner. U.K. steel and aluminum exports to the United States were slapped with a 25% tariff, in line with all other countries, when Trump unveiled the new import duties in March -- which he said were aimed at reviving domestic production -- but received a interim exemption from a doubling to 50% imposed Trump on June 4. The Business and Trade Department insisted negotiations to permanently remove the entire tariff were on track despite the waiver expiration date fast approaching in just over a week on July 9, saying Starmer and Trumo "again confirmed, we will continue go further and make progress towards 0% tariffs on core steel products as agreed." Sheffield-based Marecgaglia told the BBC that even the initial 25% was making selling to the United States a "lot tougher," and that the potential hike to 50% would be a "massive headache." The company's stainless steel products are made in the United States, but the materials such as rods and bars are shipped from the U.K. "The lead times to get it to the plant are longer than the nine days left for the negotiations. That means I would be shipping something -- and a ship will probably have around $4.1 to $5.5 million of product on it -- and I don't know will I be paying $2.1 million duty on it or zero? said managing director Liam Bates. "So it gives us an extremely hard decision to make as to how we can continue production in the US," he added.
